Abstract
Question: Should Janssen COVID-19 vaccine be recommended for persons 18 years of age and older in the U.S. under an Emergency Use Authorization?
Population: Persons 18 years of age and older
Intervention: Janssen COVID-19 vaccine (5 × 1010 viral particles, single 0.5 ml dose IM)
Comparison: No COVID-19 vaccine
Outcomes:
- Symptomatic laboratory-confirmed COVID-19
- Hospitalization due to COVID-19
- All-cause death
- SARS-CoV-2 seroconversion to a non-spike protein
- Asymptomatic SARS-CoV-2 infection
- Serious adverse events
- Reactogenicity grade ≥3
Background paper
Americas
United States of America
Janssen COVID-19 Vaccine
EtR framework
COVID-19
